Bank Of New York Mellon Corp Satsuma Pharmaceuticals, Inc. Transaction History

Bank Of New York Mellon Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$4.19 - $7.95 $68,137 - $129,282	16,262 New	16,262 $98,000
Q1 2021 May 13, 2021	BUY	$4.57 - $7.18 $39,347 - $61,819	8,610 Added 27.9%	39,472 $233,000
Q4 2020 Feb 09, 2021	BUY	$3.56 - $5.09 $20,455 - $29,247	5,746 Added 22.88%	30,862 $142,000
Q3 2020 Nov 12, 2020	SELL	$3.85 - $28.47 $8,647 - $63,943	-2,246 Reduced 8.21%	25,116 $97,000
Q2 2020 Aug 12, 2020	BUY	$16.01 - $34.69 $185,395 - $401,710	11,580 Added 73.37%	27,362 $786,000
Q1 2020 May 06, 2020	BUY	$14.53 - $30.69 $229,312 - $484,349	15,782 New	15,782 $339,000

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.